UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~the~~The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January ~~October 9~~15, ~~2009~~ 2010

DRAGON PHARMACEUTICAL INC.

(Exact name of registrant as specified in its charter)

Florida (State or Other Jurisdiction of Incorporation) ~~000~~0-27937 (Commission File Number) 65-0142474 (IRS Employer Identification No.)


650 West Georgia Street, Suite 310 Vancouver, British Columbia (Address of Principal Executive Offices)		V6B 4N9 (Zip Code)

(604) 669-8817

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 47 - ~~Matters Related to Accountants and Financial Statements~~Regulation FD

Item 4 7.01. Regulation FD ~~Changes in Registrant’s Certifying Accountant~~Disclosure.

On January 22, 2010, Dragon Pharmaceutical Inc. (athe “Company”) ~~Previous~~issued ~~Independent~~a ~~Accountants~~press release announcing that Yanlin Han, Chairman of the Board of Directors and Chief Executive Officer of the Company, made a non-binding proposal to acquire all of the outstanding shares of the Company at a price of $0.80 per share in a letter dated January 15, 2010. In addition, the Company has established a special committee of independent directors consisting of Peter Mak, Heinz Frey and Jin Li to consider the proposal and all other strategic alternatives. A copy of the press release is attached hereto as Exhibit 99.

OnSection ~~October~~ 9, ~~2009,~~– ~~Dragon~~Financial Statements ~~Pharmaceutical~~and ~~Inc. (the “Company,” “we,” “us,” or “our”) decided not to reappoint Ernst & Young LLP (“E&Y”) as our independent accountant for the year ending December 31, 2009.~~Exhibits

~~E&Y’s~~Item 9.01 Financial Statements ~~report on our consolidated balance sheets as of December 31, 2008~~ and 2007, and the related consolidated statements of operations and comprehensive income, stockholders’ equity (deficit) and cash flows for the years then ended, did not contain an adverse opinion, and was not modified as to uncertainty, audit scope or accounting principlesExhibits.

The decision to change our independent accountant was made and approved by our Audit Committee on October 9, 2009, which is comprised of independent directors who serve on the Company’s Board of DirectorsExhibit No. Exhibit Description

~~During~~99 ~~our~~Press ~~most~~release ~~recent~~dated ~~fiscal~~January ~~years ended December 31~~22, ~~2008 and 2007~~2010, ~~through~~titled ~~the~~“Dragon ~~subsequent~~Pharma ~~interim~~Receives ~~periods~~Acquisition ~~ended~~Proposal ~~March~~from ~~31,~~Yanlin 2009, June 30, 2009 and September 30, 2009, and further through October 9, 2009, there have been no disagreements with E&Y on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of E&Y, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report.Han”

~~During~~The information ~~our~~contained ~~most~~in ~~recent~~Item ~~fiscal~~7.01 ~~years~~and ~~ended~~Exhibit ~~December~~99.1 ~~31,~~attached ~~2008~~hereto ~~and~~shall ~~2007,~~not ~~through~~be deemed ~~the~~“filed” ~~subsequent~~for ~~interim~~purposes ~~periods~~of ~~ended~~Section ~~March~~18 ~~31,~~of ~~2009,~~the ~~June~~Securities ~~30,~~Exchange ~~2009~~Act of 1934, and ~~September~~shall ~~30,~~not ~~2009,~~be deemed incorporated by reference in any filing with the Securities and ~~further~~Exchange ~~through~~Commission ~~October~~under 9,the ~~2009,~~Securities ~~E&Y~~Exchange ~~did~~Act ~~not~~of ~~advise~~1934 usor the onSecurities ~~any~~Act ~~matter~~of ~~set~~1933, ~~forth~~whether inmade ~~Item~~before ~~304(a)(1)(v)(A)~~or ~~through~~after ~~(D)~~the date hereof and irrespective of ~~Regulation~~any ~~S-K~~general incorporation by reference language in any filing.

WePortions of ~~have~~this ~~provided~~report ~~our~~may ~~former~~constitute ~~independent~~“forward-looking ~~accountant,~~statements” ~~E&Y,~~defined ~~with~~by afederal law. Although ~~copy of~~ the ~~disclosures~~Company ~~expressed~~believes ~~herein~~any ~~and~~such westatements ~~have~~are ~~requested~~based ~~that~~on reasonable ~~E&Y~~assumptions, ~~furnish~~there usis ~~with~~no aassurance ~~letter~~that ~~addressed~~the toactual ~~the~~outcomes ~~Securities~~will ~~and~~not be ~~Exchange~~materially ~~Commission~~different. Any ~~stating~~such ~~whether~~statements orare ~~not~~made itin ~~agrees~~reliance ~~with~~on the ~~such~~“safe ~~statements.~~harbor” Asprotections ofprovided under the ~~date~~Private ofSecurities ~~this~~Litigation Reform ~~filing,~~Act ~~E&Y~~of ~~had~~1995. Additional ~~not~~information ~~yet furnished~~about usissues athat ~~letter.~~could lead ~~Upon~~to ~~receipt~~material ofchanges in the ~~letter,~~Company’s weperformance ~~will~~is ~~file~~contained anin ~~amendment~~the Company’s tofilings ~~this~~with ~~Form~~the ~~8-K~~Securities toand ~~include~~Exchange ~~such~~Commission ~~letter~~and asmay anbe accessed ~~exhibit~~at www.sec.gov.

~~(b) New Independent Accountants~~2

On October 14, 2009, we engaged Chang Lee LLP (“Chang Lee”) to serve as our independent registered public accounting firm for our fiscal year ending December 31, 2009. During our most recent fiscal years ended December 31, 2008 and 2007, and through the subsequent interim periods ended March 31, 2009, June 30, 2009 and September 30, 2009, up until their date of engagement, we did not consult with Chang Lee LLP regarding (i) the application of accounting principles to a specific transaction, either completed or contemplated, or the type of audit opinion that might be rendered on our financial statements, and no written SIGNATURE

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~report~~DRAGON or oral advice was provided to us that was an important factor to be considered by us in reaching a decision as to an accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as that term is defined in Item 304(a)(1)(v) of Regulation S-K)PHARMACEUTICAL INC.,

~~We have provided Chang Lee LLP with the opportunity to review the disclosure required by Item 304(~~a) ofFlorida Regulation S-K before this Form 8-K is filed with the Commission and provided them with the opportunity to furnish us with a letter addressed to the Commission containing any new information, clarification of our expression of our views, or the respects in which it does not agree with the statements made by us in response to Item 304(a) of Regulation S-K. Chang Lee LLP did not provide us with any new information, clarification of our expression of our views, or the respects in which it does not agree with the statements made by us in response to Item 304(a) of Regulation S-K. Corporation

3Dated: January 22, 2010 /s/ Maggie Deng

~~SIGNATURE~~Maggie Deng

~~Pursuant~~Chief Operating ~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~Officer

~~DRAGON PHARMACEUTICAL INC.,~~3

~~a Florida Corporation~~EXHIBIT INDEX

~~Dated: October 14, 2009~~Exhibit No. Description

~~/s/~~99 ~~Garry~~Press ~~Wong~~release dated January 22, 2010, titled “Dragon Pharma Receives Acquisition Proposal from Yanlin Han”

~~Garry Wong~~4

Chief Financial Officer

Filing Compare · DRAGON PHARMACEUTICAL INC